Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Emergency Medicine Practitioners Overall Well-being Enhancement With Ambient AI Scribes (EMPOWER)

3. august 2026 oppdatert av: Philip R.O. Payne, Washington University School of Medicine
The primary objective of the study is to investigate the impact of an ambient AI scribe on clinicians' wellness and well-being outcomes; additionally, the investigators will also explore how the use of the ambient AI scribe will lead to changes in documentation burden, clinical note characteristics and financial productivity.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

55

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Washington University School of Medicine

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Must be a Clinician (attendings and advanced practice practitioners) who is part of the Emergency Medicine Department
  • Must be willing to use Ambient AI as apart of their clinical practice work

Exclusion Criteria:

-Residents who are apart of the Emergency Medicine Department

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Ambient AI Scribe Intervention, Wave 1 (Step-wedge design)
Clinicians use an ambient AI scribe during patient encounters to assist with clinical documentation. Wave 1 participants receive the intervention for 18 weeks. Outcomes are compared before and after implementation.
Clinicians will use an ambient AI scribe as part of routine clinical care. The AI scribe captures the patient-clinician conversation, generates a draft clinical note, and supports documentation in the electronic health record. Clinicians receive training before beginning use of the AI scribe. The intervention is introduced in three sequential waves using a stepped-wedge design, with all participants eventually receiving the intervention.
Eksperimentell: Ambient AI Scribe Intervention, Wave 2 (Step-wedge design)
Clinicians use an ambient AI scribe during patient encounters to assist with clinical documentation. Wave 2 participants receive the intervention for 12 weeks. Outcomes are compared before and after implementation.
Clinicians will use an ambient AI scribe as part of routine clinical care. The AI scribe captures the patient-clinician conversation, generates a draft clinical note, and supports documentation in the electronic health record. Clinicians receive training before beginning use of the AI scribe. The intervention is introduced in three sequential waves using a stepped-wedge design, with all participants eventually receiving the intervention.
Eksperimentell: Ambient AI Scribe Intervention Wave 3 (Step-wedge design)
Clinicians use an ambient AI scribe during patient encounters to assist with clinical documentation. Wave 1 participants receive the intervention for 6 weeks. Outcomes are compared before and after implementation.
Clinicians will use an ambient AI scribe as part of routine clinical care. The AI scribe captures the patient-clinician conversation, generates a draft clinical note, and supports documentation in the electronic health record. Clinicians receive training before beginning use of the AI scribe. The intervention is introduced in three sequential waves using a stepped-wedge design, with all participants eventually receiving the intervention.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Impact of an ambient AI scribe on clinician well-being and professional fulfillment
Tidsramme: From enrollment to the end of maintenance phase at 24 weeks
A linear model will be used to describe the effect of Ambient tool introduction on our co-primary outcomes under the intention-to-treat framework with a random effects structure to describe within provider variability. While high or complete survey completion rates is expected, in the event that not all surveys are completed and returned, a primary analysis on completed surveys only will be performed, and perform sensitivity analyses accounting for potentially systematic survey non-response bias using a response weighting strategy, using provider, scheduling, and patient encounter characteristics to create survey response weights (within each survey time period), then reweighting observations to account for non-response patterns. In analyses for both co-primary outcomes, Wald type hypothesis tests for inferences on the overall Ambient treatment effect and compare p-values to 0.05 / 2 to conservatively account for multiple comparisons using Bonferroni's method will be performed.
From enrollment to the end of maintenance phase at 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Assessment of the longitudinal changes in documentation burden
Tidsramme: From enrollment to the end of maintenance phase at 42 weeks
The investigators will fit Bayesian generalized linear models with appropriate link functions and likelihood choices (ie, log and Poisson for count data, logit and Bernoulli for binary responses) to for each encounter, while accounting for serial correlation overall through time (indexed to the day) using an autoregressive modeling structure, within provider patterns using a provider level random intercept, weekday, weekend, and holiday effects using fixed effects terms, and specify a flexible interrupted time series treatment effect using a semi-parametric, thin plate spline to describe how the introduction of Ambient AI affects the relationship between providers and notes, and how that relationship evolves over time. In sensitivity analyses, evaluation of how these effects and their evolution may differ by treatment wave will be assessed. All inferences will be based on describing the mean and 95% credible intervals for the treatment effect daily.
From enrollment to the end of maintenance phase at 42 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Thomas Kannampallil, PhD, Washington University in Saint Louis

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. april 2026

Primær fullføring (Antatt)

1. desember 2026

Studiet fullført (Antatt)

1. juli 2027

Datoer for studieregistrering

Først innsendt

21. juli 2026

Først innsendt som oppfylte QC-kriteriene

28. juli 2026

Først lagt ut (Faktiske)

3. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 202602161

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere